Dialectic Therapeutics, Inc

Lantern Pharma Inc. is a clinical stage biotechnology company based in Dallas, Texas, dedicated to innovating the cancer drug development process through advanced genomics, machine learning, and artificial intelligence. Their proprietary A.I. platform, RADR, encompasses over 100 billion data points to identify genomic signatures correlated with drug response, facilitating the development and repositioning of cancer therapies for patients. The company's portfolio includes three lead drug candidates and an antibody-drug conjugate (ADC) program targeting 12 cancer indications, with one candidate in phase 2 clinical testing and two others recently entering phase 1 trials. Lantern Pharma employs a data-driven, biomarker-focused strategy to accelerate drug development while minimizing costs compared to traditional methods. Generated from the website

Vaxxinity, Inc, based in Dallas, TX, is a pioneering biotech company on a mission to democratize health by revolutionizing the treatment of chronic diseases. Through their innovative platform, they aim to provide cheaper, safer, and more convenient medicines for chronic conditions, with a focus on developing vaccines and monoclonal antibodies. With a commitment to tackling diseases that affect billions of people worldwide, Vaxxinity is pushing the boundaries of medical science to bring about a new era of therapeutics. Driven by an expansively disruptive approach, Vaxxinity is at the forefront of the third biologic revolution, leveraging the efficiency of vaccines and the validation of monoclonal antibodies in chronic disease treatment. Their groundbreaking research and development efforts encompass a wide range of conditions, including Alzheimer's, Parkinson's, migraine, hypercholesterolemia, and more. With a vision to bring more health to more people, Vaxxinity is boldly venturing into uncharted territories, aiming to make a significant impact on global healthcare.Generated from the website

Nanoscope Therapeutics, Inc., based in Dallas, TX, is pioneering a new generation of optogenetic therapies aimed at restoring vision lost to inherited retinal diseases. With a commitment to improving the lives of patients, the company emphasizes compassion and innovation in its mission to bring back hope and independence to those affected by vision loss. Utilizing its advanced multi-characteristic opsin (MCO) platform, Nanoscope has developed MCO-010, the first broad spectrum and ultra-sensitive optogenetic technology capable of restoring vision in patients with severe vision loss. Through its ongoing clinical trials and patient-centered initiatives, the organization continues to drive advancements in therapeutic possibilities for retinal disease. Generated from the website